Cipla Unit Received a Voluntary Action Indicated Status From the USFDA

Cipla Ltd, a leading Indian multinational pharmaceutical powerhouse headquartered in Mumbai, has been synonymous with affordable yet cutting-edge healthcare solutions since its inception in 1935. 

The company holds a distinguished reputation in respiratory, oncology, cardiovascular, and anti-infective therapies. With a formidable global footprint spanning over 80 countries, Cipla boasts an extensive portfolio of both branded and generic medicines.

Received Status From USFDA

Cipla Ltd disclosed that its manufacturing facility in Virgonagar, Bengaluru, had received a Voluntary Action Indicated (VAI) status from the United States Food and Drug Administration (USFDA). 

A VAI designation implies that while the inspection identified certain objectionable conditions or practices, the regulatory body does not currently intend to pursue administrative or enforcement actions. 

This rating is notably more favourable than the Official Action Indicated (OAI) status, which typically calls for regulatory interventions. The inspection in question, a routine evaluation of compliance with current Good Manufacturing Practices (cGMP), was conducted by the USFDA between November 7 and November 13, 2024.

Cipla Q3 FY25 Results

Cipla Ltd. continues to deliver an impressive financial performance. The company reported a stellar 49% year-on-year surge in net profit to ₹1,574.6 crore for Q3 FY25, compared to ₹1,068.5 crore during the same period last year. 

Revenue from operations grew by 7% year-on-year to ₹7,073 crore, bolstered by a strong 10% uptick in the Indian market, which contributed ₹3,146 crore.

North American revenues stood at $226 million, reflecting a marginal 1% dip attributable to supply chain disruptions. Nonetheless, EBITDA expanded by a remarkable 15.7% year-on-year to ₹1,989 crore, with margins climbing 184 basis points to a record-breaking 28.1%.

Share Price Performance 

At 2:22 PM on February 10, 2025, Cipla Ltd shares traded at ₹1,454.40 per share on the NSE.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.